AbbVie Strikes Deal With Lupin for Blood Cancer Program
AbbVie Strikes Deal With Lupin for Blood Cancer Program
Investing Into R&D Pays off for Some of Biotech’s Biggest Companies
Investing Into R&D Pays off for Some of Biotech’s Biggest Companies
Pfizer secures 4th cancer drug approval in 2 months
Pfizer secures 4th cancer drug approval in 2 months
On a roll with FDA approvals, Pfizer doubles down in AML with Daurismo nod
On a roll with FDA approvals, Pfizer doubles down in AML with Daurismo nod
AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML
AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML
FDA Approves DAURISMO™ (glasdegib) for Acute Myeloid Leukemia (AML)
FDA Approves DAURISMO™ (glasdegib) for Acute Myeloid Leukemia (AML)
